Mavyret, a treatment for hepatitis C, does not currently have a generic version available. The drug is manufactured by AbbVie [1].
When Might a Mavyret Generic Be Available?
The patent protection for Mavyret plays a significant role in determining when generic versions can enter the market. Patent expiry dates dictate the period of market exclusivity for the original drug manufacturer [2]. Information on specific patent expiry dates for Mavyret can be found on resources like DrugPatentWatch.com [2].
What Factors Influence Generic Drug Availability?
Beyond patent expiry, other factors can influence the availability of generic drugs. These include regulatory approvals from agencies like the U.S. Food and Drug Administration (FDA), which must confirm that a generic drug is bioequivalent to its brand-name counterpart and meets all safety and efficacy standards [3]. The complexity of the drug's manufacturing process can also impact how quickly a generic can be developed and approved [3].
How Does Mavyret Work?
Mavyret is a combination therapy consisting of two active ingredients: glecaprevir and pibrentasvir [1]. Glecaprevir is an NS3/4A protease inhibitor, while pibrentasvir is an NS5A inhibitor. Both target and inhibit the hepatitis C virus's ability to replicate [4].
Who Else Manufactures Hepatitis C Treatments?
Several companies are involved in the development and manufacturing of hepatitis C treatments. These include, but are not limited to, Gilead Sciences, Bristol Myers Squibb, and Merck & Co., which offer various direct-acting antiviral (DAA) medications for hepatitis C [5].
What is the Cost of Mavyret?
The cost of Mavyret, like many prescription medications, can vary based on insurance coverage, pharmacy, and geographic location. Without a generic available, patients are typically subject to the brand-name drug's pricing [1].
---
Cited Sources
1. AbbVie. (n.d.). Mavyret (glecaprevir/pibrentasvir). Retrieved from https://www.mavyret.com/
2. DrugPatentWatch.com. (n.d.). Mavyret patent information. Retrieved from https://drugpatentwatch.com/
3. U.S. Food and Drug Administration. (n.d.). Generic Drugs: Questions & Answers. Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drugs-questions-answers
4. E ACS. (n.d.). Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144928/
5. National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Hepatitis C Treatments. Retrieved from https://www.niddk.nih.gov/health-information/liver-disease/hepatitis-c/treatments